News & Events
Having HIV, and presumably being on antiretroviral therapy, may reduce the risk of developing MS
Neurofilaments are a good way to monitor nerve damage and treatments in progressive MS
Natalizumab is associated with clinically meaningful improvements in walking speeds
Researchers found a lower risk of disability progression at the 10-year follow-up in the RRMS group compared…
DMSG’s training programme aims to help people with MS improve cognition functions
Abdelfatah Ibrahim’s visit focused on supporting a new MS/NMO group
Deep grey matter is profoundly involved in the disease progression of MS patients
The presence of iron could help us understand the MS inflammation process
Patients with secondary progressive MS who have ongoing relapses may benefit from continuing immunomodulatory therapies after onset…
Over 35 per cent of patients with clinically isolated syndrome were diagnosed earlier when applying the 2010…
The results suggest that primary progressive and relapsing forms of MS have different underlying mechanisms
Switching patients with relapsing-remitting MS from interferon to glatiramer acetateis associated with positive treatment outcomes